CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 131 enrolled
Drug / intervention
Orlistat +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00752726
NCT00752726Phase 4Completed
CompareCT.gov

The Effects of Weight Reduction With Orlistat vs. Placebo on Changes in Body Composition

GlaxoSmithKline·interventional·Posted Sep 15, 2008·Updated Mar 8, 2013

In Brief

A Phase 4 clinical trial evaluating Orlistat and Placebo for Obesity and Overweight. Completed, enrolled 131 participants across 3 sites in 2 countries.

Detailed Summary

The purpose of this study is to determine if a 24 week weight loss program with orlistat 60 mg will produce greater changes in body composition compared to placebo.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsObesity, Overweight
CountriesSweden, United States
Collaborators--

Timeline

Phase 4CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedSep 15, 2008
Enrollment StartSep 1, 2008
Primary CompletionJul 1, 2009
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 17.8 years ago

Interventions

Orlistatdrug

Weight loss treatment

Placebodrug

Inactive